Elam M B, Lipscomb G E, Chesney C M, Terragno D A, Terragno N A
Prostaglandins. 1980 Dec;20(6):1039-51. doi: 10.1016/0090-6980(80)90058-1.
Treatment of adult female New Zealand white rabbits with ethinyl estradiol, the synthetic estrogen used in many oral contraceptives, results in a significant increase in in vivo aggregation. This alteration in platelet behavior is accompanied by diminished vascular release of antiaggregatory PGI2 (prostacyclin)-like material. Addition of a progestin prevents the change in platelet aggregation seen with the estrogen alone. Diminished vascular PGI2 release may be an important factor in the pathogenesis of thrombotic occurrences experienced by some oral contraceptive users. In vivo platelet aggregation may be of value in identifying individuals at risk of developing thrombotic disturbances while taking oral contraceptives.
用炔雌醇（许多口服避孕药中使用的合成雌激素）治疗成年雌性新西兰白兔，会导致体内血小板聚集显著增加。血小板行为的这种改变伴随着抗聚集性前列环素（PGI2）样物质的血管释放减少。添加孕激素可防止单独使用雌激素时出现的血小板聚集变化。血管PGI2释放减少可能是一些口服避孕药使用者发生血栓形成的发病机制中的一个重要因素。体内血小板聚集对于识别服用口服避孕药时发生血栓紊乱风险的个体可能具有价值。
